SkyOak Wealth’s Lineage Cell Therapeutics LCTX Stock Holding History

SkyOak Wealth’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Hold	15,000	–	–	﹤0.01%	251
2026 Q1	$23.7K	Hold	15,000	–	–	﹤0.01%	254
2025 Q4	$25.1K	Hold	15,000	–	–	﹤0.01%	249
2025 Q3	$25.4K	Hold	15,000	–	–	﹤0.01%	247
2025 Q2	$13.6K	Hold	15,000	–	–	﹤0.01%	243
2025 Q1	$6.77K	Hold	15,000	–	–	﹤0.01%	242
2024 Q4	$7.54K	Hold	15,000	–	–	﹤0.01%	253
2024 Q3	$13.6K	Hold	15,000	–	–	﹤0.01%	239
2024 Q2	$15K	Hold	15,000	–	–	﹤0.01%	240
2024 Q1	$22.2K	Hold	15,000	–	–	0.01%	243
2023 Q4	$16.4K	Hold	15,000	–	–	﹤0.01%	236
2023 Q3	$17.7K	Hold	15,000	–	–	0.01%	233
2023 Q2	$21.1K	Hold	15,000	–	–	0.01%	239
2023 Q1	$22.5K	Hold	15,000	–	–	0.01%	248
2022 Q4	$17.6K	Hold	15,000	–	–	0.01%	226
2022 Q3	$17K	Hold	15,000	–	–	0.01%	216
2022 Q2	$24K	Hold	15,000	–	–	0.01%	219
2022 Q1	$23K	Hold	15,000	–	–	0.01%	239
2021 Q4	$37K	Hold	15,000	–	–	0.01%	244
2021 Q3	$38K	Hold	15,000	–	–	0.01%	230
2021 Q2	$43K	Hold	15,000	–	–	0.01%	235
2021 Q1	$40K	Hold	15,000	–	–	0.01%	234
2020 Q4	$26K	Hold	15,000	–	–	0.01%	215
2020 Q3	$14K	Hold	15,000	–	–	0.01%	204
2020 Q2	$13K	Hold	15,000	–	–	﹤0.01%	237
2020 Q1	$12K	Hold	15,000	–	–	0.01%	210
2019 Q4	$13K	Buy	+15,000	New	+$12.5K	﹤0.01%	309

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SkyOak Wealth's LCTX Position: Q2 2026 in Review

SkyOak Wealth held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 15,000 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

SkyOak Wealth first reported a position in LCTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $43K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

SkyOak Wealth held 15,000 shares of Lineage Cell Therapeutics worth $19.6K as of Q2 2026.
SkyOak Wealth left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of SkyOak Wealth's portfolio in Q2 2026, its #251 holding.
SkyOak Wealth first reported a position in Lineage Cell Therapeutics in Q4 2019 and has held it in 27 quarters since.
SkyOak Wealth's Lineage Cell Therapeutics position peaked at $43K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on SkyOak Wealth's 13F filing for Q2 2026, filed 30 Jul 2026.